Revolution Medicines

Senior Director, Head of Transactions & Partnering

Redwood City, California, United States · Director · Full-time

Sponsorship not specified$244k-$305kDetected 22 hours ago

ComplianceBusiness DevelopmentNegotiationValuationFP&AIntellectual PropertyResearchLeadershipCommunicationCollaborationProblem SolvingPublic Speaking

About the role

The successful candidate will bring deep transaction expertise, strong business judgment, and exceptional negotiation skills, coupled with the ability to lead complex cross-functional teams and drive alignment among diverse stakeholders.
This individual will play a critical role in enabling Revolution Medicines to establish and execute strategic partnerships that accelerate innovation, expand capabilities, and create long-term value for patients and shareholders.
The Senior Director, Head of Transactions and Partnering is a senior leader within the Business Development organization responsible for leading the evaluation, structuring, negotiation, and execution of strategic business development transactions that support Revolution Medicines' corporate and portfolio objectives.

Lead the company's transaction activities, advancing prioritized opportunities from evaluation through execution.
Serve as the transaction lead for strategic business development opportunities, developing negotiation strategies and execution plans that maximize value and support corporate objectives.
Lead transaction processes from initial engagement through confidentiality agreements, term sheet development, definitive agreement negotiation, and transaction closing.
Develop creative transaction structures that appropriately balance strategic objectives, economics, operational considerations, and risk allocation.
Identify transaction risks and develop practical solutions that facilitate successful deal execution while protecting the company's interests.
Serve as Revolution Medicines' lead negotiator for strategic business development transactions.
Partner closely with finance and legal/transaction counsel to develop transaction structures, review and negotiate definitive agreements, and drive successful deal execution.
Collaborate with FP&A, commercial, competitive intelligence, business development team members to evaluate transaction economics, valuation analyses, and investment considerations.
Lead negotiations involving scientific, clinical, commercial, intellectual property, operational, and financial elements of complex transactions.
Develop and execute negotiation strategies that maximize value creation while preserving long-term partnership success.

12+ years of relevant experience in biotechnology or pharmaceutical business development, transactions, corporate strategy, or related disciplines.
Demonstrated track record of leading and executing multiple complex strategic transactions, including licensing, collaboration, co-development, alliance, acquisition, or other business development agreements.
Strong understanding of intellectual property considerations, licensing frameworks, and strategic partnership models within the life sciences industry.

Advanced degree in life sciences, medicine, pharmacy, business, or a related field
MBA, PhD, MD, PharmD preferred.

Advanced degree in life sciences, medicine, pharmacy, business, or a related field; MBA, PhD, MD, PharmD preferred.
Significant experience independently leading negotiations from initial engagement through definitive agreement execution.
Deep understanding of biopharmaceutical drug development, transaction structures, valuation methodologies, and deal economics.
Exceptional strategic thinking, analytical, and problem-solving skills.
Outstanding communication, presentation, and influencing capabilities, including experience presenting recommendations to senior executives.
Ability to thrive in a fast-paced, highly collaborative, and evolving environment.
Experience supporting transactions involving oncology therapeutics, precision medicine, targeted therapies, or related technologies.
Experience within both large pharmaceutical and emerging biotechnology environments.
Established network across biotechnology, pharmaceutical, venture capital, and academic communities.
Experience supporting global transactions involving multiple geographies and stakeholders.
Leadership Competencies
Successful candidates will demonstrate:

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers.
The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

This listing is sourced directly from Revolution Medicines's careers page and normalized into a canonical job model.